Fintel reports that on June 24, 2025, Stephens & Co. upgraded their outlook for Exelixis (NasdaqGS:EXEL) from Equal-Weight to ...

Investors in Exelixis Inc (Symbol: EXEL) saw new options become available this week, for the February 2026 expiration. One of the key data points that goes into the price an option buyer is ...

Investors in Exelixis Inc (Symbol: EXEL) saw new options become available this week, for the May 2024 expiration. One of the key data points that goes into the price an option buyer is willing to ...

EXEL stands above TECH thanks to its solid earnings outlook, and based on these valuation figures, we also feel that EXEL is the superior value option right now.

EXEL continues to successfully implement Farallon's restructuring suggestions. A pivotal decision on cabo's current patent litigation is due by end of 1H'24. Multiple billions of potential revenue ...

EXEL currently has a forward P/E ratio of 16.66, while ARGX has a forward P/E of 43.23. We also note that EXEL has a PEG ratio of 0.79. This popular figure is similar to the widely-used P/E ratio ...

Another notable valuation metric for EXEL is its P/B ratio of 4.54. The P/B is a method of comparing a stock's market value to its book value, which is defined as total assets minus total liabilities.

Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Exelixis (EXEL) and Techne (TECH). But which of these two companies is the best option for those looking for ...